Kensey Nash, a medical device company primarily focused on regenerative medicine utilizing its proprietary collagen and synthetic polymer technology, has acquired Synthes' Norian subsidiary assets for $22m.
Synthes globally distributes the orthobiosurgery products portfolio currently manufactured by Norian.
As part of a long-term supply agreement, Kensey Nash will manufacture the Norian products, and Synthes will exclusively distribute the products worldwide.
The Norian portfolio consists of approximately a dozen biomaterial-based surgical products including: the beta-tricalcium phosphate chronOS Preforms and chronOS Strip; the SynPOR Porous Polyethylene Implants; and the Norian family of calcium phosphate bone cements, which include reinforced and fast setting products as part of the Norian Skeletal Repair System and Norian Craniofacial Repair System product lines.
The addition of Norian’s orthobiosurgery and other key biomaterial products is expected to allow Kensey Nash to further its penetration into the regenerative medicine markets encompassing soft tissue surgical repair, orthopaedics, sports medicine, spine and neurosurgery.
In addition, the companies entered into a research and development agreement to create certain related future products.
Kensey Nash will transition the Norian product manufacturing operations from Synthes’ current facility in West Chester, PA to the Kensey Nash Exton, PA facility over a two year period.
Synthes has also entered into a long-term lease to use Norian manufacturing building after Kensey Nash transfers the manufacturing into its Exton facility.